Dhanuka Agritech Update

Reasons for buying:

Buy PE was reasonable at 14.52 below the 10-year PE median of 19.61.

The 5-year earnings average is 13.43% and earnings increasing since 2013 with a slight blip in 2020.

Return on equity is good at 23% but the 5-year average is 22%.

The market cap of the company is ₹3,069 Cr.

The debt of the company is ₹0.96Cr with ₹198 Cr cash.

Buy date: 03-Oct-2022

Qty: 15 Buy Price: ₹653 Buy EPS: ₹44.96 Buy PE: 14.52

I will stop adding when EPS drops below ₹32.65 or R3 does not satisfy.

Buyback

Qty:8 Sell Price: ₹850 Sell EPS: ₹47.03 Sell PE: 18.07

Profit: ₹1,576

Dhanuka Agritech is involved in the manufacturing and marketing of plant protection agrochemicals. The product range consists of Insecticides, Herbicides, Fungicides, and plant growth regulators. The company offers crop solutions for various crops. Its brand portfolio consists of more than 85 brands. The firm generates a majority of its revenue from agrochemicals. The company has a strategic partnership with American, Japanese, and European companies. Its manufacturing facilities are located in Gurgaon (Haryana), Sanand (Gujarat),, Udhamput (Jammu and Kashmir), and Keshwana (Rajasthan). Dhanuka's target customers are farmers.

6 Sanofi India Update

Reasons for buying:

Market Cap: ₹13,602 Cr (Bluechip stock)

Debt to Equity: 0.05

Return on Equity 5Y Avg: 23.83%

EPS - 5Y Growth: 29.46%

Price-earnings to growth (5Y): 0.47

5Y RoE Consistency - Sustained without losing 20% in any year

Buy date: 4-Apr-2022

Qty: 1 Buy Price: ₹7,400 Buy EPS: 410.06

Buy date: 10-May-2022

Qty: 1 Buy Price: ₹6,660 Buy EPS: 450.22

Buy date: 23-Sep-2022

Qty: 1 Buy Price: ₹5,908.95 Buy EPS: 425.08

The yield is 3% and paid dividend continues with good fundamentals so added more.

Buy date: 23-Dec-2022

Qty: 12 Price: ₹5833.85 EPS: ₹251.88

Will continue to add when a stock falls 10% as long as the ratios remain the same. The stock would take a long time to pay, it lost 20% since I bought it in April.

Sanofi India is a drug manufacturing company that focuses on a range of therapeutic areas, including Diabetes, Cardiology, Consumer Healthcare, Hospitals, Central Nervous systems, and Anti-Histamines. The company's diabetes presence includes oral anti-diabetic products and insulin. The consumer healthcare area also maintains a nutraceutical portfolio. The company's export markets include Germany, the U.K., Australia, and Russia. The company utilizes strategic partnerships as a component of its growth strategy.

5 Sutlej Textiles and Industries Update

The stock came up on the HDY screen and I will hold it for longer and hope the company pays dividends.

***

Buy date: 23-Dec-2022

Qty: 1690 Price: ₹59.15 EPS: ₹10.06

The stock came up on the HDY screen and will hopefully sell in a short period of time.

***

Buy date: 14-Nov-2022

Qty: 163 Price: ₹61 EPS: ₹10.06

Sell date: 30-Nov-2022

Qty: 163 Price: ₹62.3 EPS: ₹10.06

Profit: ₹211.9

***

Will sell if it is not present on the screen

3 Cosmo First Update

The stock came up on the HDY screen and I will hold it for longer and hope the company pays dividends.

Buy date: 13-12-2022

Qty: 130 Price: ₹767 EPS: ₹146.6

The stock came up on the HDY screen and will hopefully sell in a short period of time.

***

Buy date: 15-Nov-2022

Qty: 14 Price: ₹690 EPS: ₹146.6

Sold Date: 30-Nov-2022

Qty: 14 Price: ₹796.95 EPS: ₹146.6

Profit: ₹1,497.3

***

Will sell if it is not present on the screen

1 Manali Petrochemicals Update

Reasons for buying:

Buy PE was reasonable at 4.19 and below 10 years PE median of 6.75.

The 5-year earnings average is 33.22% but lackluster for years.

Return on equity is good at 34.66% but the 5-year average is 18.34%.

The market cap of the company is ₹1,670.11 Cr.

The debt of the company is ₹14.28 Cr with ₹286.96 Cr in cash.

Buy date: 02-Mar-2022

Qty: 103 Buy Price: ₹96.55 Buy EPS: ₹23.16 Buy PE: 4.19

I will stop buying when EPS drops to 4.8275

Stock is yielding 3% at ₹83.1 and will hold forever max risk is 1lakh if the stock goes to zero.

Buy date: 12-Dec-2022

Qty: 1098 Buy Price: ₹83.1 Buy EPS: ₹13.49

Manali Petrochemicals Ltd operates in the chemical industry. The company is engaged in the manufacture and sale of Propylene Oxide (PO), Propylene Glycol (PG), and Polyols (PY). It serves various industries such as appliances, automotive, bedding, food and fragrances, furniture, footwear, paints and coating, and pharmaceuticals. The company's only operating segment includes the manufacture and sale of petrochemical products. Geographically, it operates only in India.

Aarti Industries Update

Reasons for buying:

Market Cap: ₹28,306 Cr (Bluechip stock)

Debt to Equity: 0.16

Return on Equity 5Y Avg: 22.26%

EPS - 5Y Growth: 30.27%

Price-earnings to growth (5Y): less than 1.5

5Y RoE Consistency - Sustained without losing 20% in any year

***

Buy date: 9-Sep-2022

Qty: 11 Buy Price: ₹854.85 Buy EPS: 36.73

New Price after demerger: ₹646.10

***

Buy date: 29-Sep-2022

Qty: 13 Buy Price: ₹769 Buy EPS: 36.73

New Price after demerger: ₹581.21

Will continue to add when a stock falls 10% as long as the ratios remain the same. The stock would take a long time to pay, it lost 10% in 20 days.

***

Buy date: 20-Oct-2022

Qty: 14 Price: ₹683 EPS: 36.73

***

Due to the demerger, the cost of the acquisition of my shares changed.

Sr. No. Name of the Company Percentage of cost of acquisition of equity shares

1 Aarti Pharmalabs Limited (Resulting Comoanvl 24.42%

2 Aarti Industries Limited (Dernerged Cornoanvl 75.58%

Total 100.00% 

Aarti Industries manufactures and sells chemicals and chemical-based products in two segments based on the product type. The specialty chemical segment which generates the majority of revenue sells benzene-based chemicals which are used in agricultural products dyes and pigments and flavors and fragrances. The pharmaceuticals segment sells drugs used to treat diarrhea, inflammation, and asthma as well as antibiotics and antidiabetics. More revenue comes from India than any other country or region.

Maharashtra Scooters

This is part of book value investing

PB<.5

Book value growth 10Y and 5Y more than 10%.

Book Value: 20309

Buy date: 30-Nov-2022

Qty: 2 Price: ₹4974.75 EPS: ₹171.8 PB: 0.26

I will sell at book value and plan to update the GTT order in Zerodha every week by checking Tradeview. If the book value decreases I will lose money otherwise hoping the company can increase book value and sell it at book value a few years from now. Usually, book value investing takes at least 5 years and in some cases can hit PB =1 once in 10 years. In this case, it may not hit PB=1 and hope to collect dividends. I will not average this stock if earnings fall.

Kwality Pharmaceuticals

Reasons for buying:

Buy PE was reasonable at 7.9 and the 10-year median PE is 22.

The 5-year earnings average is 104% and earnings increasing since 2014.

Return on equity is good at 99.05% but the 5-year average is 37.25%.

The market cap of the company is ₹3,560 Cr.

The debt of the company is ₹54.01 Cr with ₹12.95 Cr cash.

Buy date: 23-N0v-2022

Qty: 29 Buy Price: ₹343.5 Buy EPS: ₹43.46 Buy PE: 7.9

Will add to stock only if earnings rise and price drops.

Kwality Pharmaceuticals is an India-based pharmaceutical company. it is principally engaged in manufacturing finished pharmaceutical formulations in a dosage form. The company manufactures and exports pharmaceutical formulations in liquid orals, dry syrups, tablets, capsules, sterile powder for injections, and small-volume injectables. It also manufactures veterinary pharmaceutical products.

Polyplex Corp Update

I may have purchased at high PE of 12.75 considering the 10-year PE median is 6.75.

Buy Date: 28-Jun-2022

Qty: 4    Price: ₹2,311    EPS: ₹181.79    PE: 12.75

The reason for adding is EPS has increased from ₹181.19 to ₹211.29

Buy Date: 21-Nov-2022

Qty:5    Price: ₹1,845.9    EPS: ₹211.29    PE: 8.73

ROE is 18.87 and 5-year ROE is 12.66

Debt/Equity is 0.25

5-year EPS growth is 21.22

Polyplex Corp is an India-based company engaged in the manufacturing of plastic films. The company diversified its business under Polyethylene Terephthalate films. Cast Polypropylene films, and Biaxially Oriented Polypropylene. These products act as raw materials for their product applications like packaging, industrial, and specialties, electrical, roofing, and others. Geographically, it derives a majority of its revenue from Outside India.

Nava

The stock came up on the HDY screen and will hopefully sell in a short period of time.

Buy date: 16-Nov-2022

Qty: 53 Price: ₹187.05 EPS: ₹60.41

Will sell if it is not present on the screen

Cyient update

Ex-Dividend date 25-10-2022 ₹10 per share. Received ₹130 the cost basis is ₹9630.4.

I just wanted to try dividend investing, will check yearly to see how it performed.

Buy Date: 17-Oct-202296

Qty: 13 Price: ₹750.8 EPS: ₹43.83 Amount: ₹9760.4

Dividend Evaluation Checklist:
3.19	Dividend Yield: Ideally Between 3.5% and 6.5%
The dividend growth is not consistent year on year	Number of Consecutive Years of Dividend Growth: Ideally At Least 10
41.17%	Average Annual Dividend Growth: Ideally between 5% and 10%
12.62%	Average Annual Earnings Growth: Ideally in line with or above dividend growth rates.
54.78	Dividend Payout Ratio: Ideally less than 75%, except for REITs and MLPs
0.52	Debt to Equity Ratio: Ideally 1:1 or less
11.52	Net Margins: Ideally at least 5%
16.29	Return on Equity: Ideally at least 10%
949	Fair Value Estimate: Ideally trading below Morningstar’s Fair Value Estimate
750.8	Current Price

I will continue to invest only when EPS increases and the price falls.

I am going to sell it at Morningstar's Fair Value.

Cyient provides a variety of information technology, IT, and engineering services. The firm organizes itself into two segments based on customer type and reported as either service or design-led manufacturing revenue. Services are by far the largest activity. The industries served are aerospace and defense, communications, energy and utilities, transportation, medical and healthcare, semiconductor, and portfolio which focuses on the development and implementation of new technologies in all sectors. The majority of the company's revenue comes from America.

Sandur Manganese and Iron Ores added

Reasons for buying:

Buy PE was reasonable at 3.38 and below 10 years PE median of 11.94.

Earnings have increased since 2016.

Return on equity is at 75%.

The market cap of the company is ₹1,892cr.

The debt of the company is ₹308cr with ₹1114cr in cash.

Buy date: 22-Feb-2022

Qty: 9 Buy Price: ₹920.02 Buy EPS: 189.03 Buy PE: 4.86

Buy date: 11-Oct-2021

Qty: 12 Buy Price: ₹828 Buy EPS: 208.67 Buy PE: 3.96

Buy date: 14-Oct-2022

Qty: 14 Buy Price: ₹705.9 Buy EPS: 208.67 Buy PE: 3.38

I will stop buying when EPS drops to 46 or when R1 is not satisfied.

Sandur Manganese and Iron Ores is a mining company. It is engaged in the mining of manganese and iron ore. The company is also engaged in the manufacture of ferroalloys. Its operating segment includes Mining and Ferroalloys and Coke and energy. The company generates maximum revenue from the Coke and Energy segment. Geographically, it derives all of its revenue from India.

IG Petrochemicals added

Reasons for buying:

Buy PE was reasonable at 11.84 and above 10 years PE median of 10.54.

Earnings have increased 14 times since 2012 although not consistently.

Return on equity is ok at 25.86%.

The market cap of the company is ₹2,846.21cr.

The debt of the company is ₹163.91cr with ₹83.55cr in cash.

Buy date: 11-Oct-2021

Qty: 10 Buy Price: ₹913 Buy EPS: 77.08 Buy PE: 11.84

The price of the stock is down about -23.11% from my buy price. I will stop buying when EPS drops to 45.65.

Buy date: 20-Oct-2021

Qty: 12 Buy Price: ₹821.00 Buy EPS: 77.08 Buy PE: 10.65

The earnings have increased by 17.64%.

Buy date: 17-Nov-2021

Qty: 13 Buy Price: ₹722.00 Buy EPS: 90.68 Buy PE: 7.96

Buy date: 25-Jan-2022

Qty: 15 Buy Price: ₹639.00 Buy EPS: 90.68 Buy PE: 7.047

Buy date: 12-Oct-2022

Qty: 18 Buy Price: ₹547 Buy EPS: 95.47 Buy PE: 5.72

I will sell when EPS falls below 45.65 or R1 is not satisfied.

IG Petrochemicals Ltd is engaged in the manufacture and sale of organic chemicals. It produces Phthalic Anhydride, Maleic Anhydride, and Benzoic Acid. The Phthalic Anhydride is used for the manufacture of polyvinyl chloride products for the manufacturing of a range of consumer care, personal care, and home care products like shoes, pipes and hoses, boxes, containers, packaging films, medical and surgical equipment, and others. In addition, it is also used as the thermostat for the manufacture of fiberglass-reinforced plastics for the automobile, construction, marine, and transportation industries. Geographically, the firm has a presence in both the Indian and international markets of which the Indian region accounts for the majority of revenue.

Gujarat State Fertilizers & Chemicals

This is part of book value investing

PB<.5

Book value growth 10Y and 5Y more than 10%.

Book Value: 295

Buy date: 10-Oct-2022

Qty: 76 Price: ₹130.85 EPS: ₹27.81 PB: 0.44

I will sell at book value and plan to update the GTT order in Zerodha every week by checking Tradeview. If the book value decreases I will lose money otherwise hoping the company can increase book value and sell it at book value a few years from now. Usually, book value investing takes at least 5 years and in some cases can hit PB =1 once in 10 years.

Kopran added

Reasons for buying:

Buy PE was reasonable at 19.43 and above 10 years PE median of 11.22.

The 5-year earnings average is 25.2% and earnings are lackluster.

Return on equity is good at 28.34% but the 5-year average is 17.67%.

The market cap of the company is ₹1,285.05 Cr.

The debt of the company is ₹66.30 Cr with ₹7.98 Cr in cash.

Buy date: 28-Apr-2022

Qty: 38 Buy Price: ₹263 Buy EPS: 13.53 Buy PE: 19.43

***

Buy date: 12-May-2022

Qty: 42 Buy Price: ₹229.85 Buy EPS: 13.54 Buy PE: 16.98

***

Buy date: 06-July-2022

Qty: 50 Buy Price: ₹196.7 Buy EPS: 14.24 Buy PE: 13.81

***

Buy date: 16-Aug-2022

Qty: 54 Buy Price: ₹184 Buy EPS: 13.86 Buy PE: 13.27

***

Buy date: 03-Oct-2022

Qty: 63 Buy Price: ₹157 Buy EPS: 13.86 Buy PE: 11.32

I will stop buying when EPS drops to 13.15 since I have purchased at 20 PE.

Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. It operates through the following business units: Formulations, and Active Pharmaceutical Ingredients. The firm's products include Amyn, Lokit, and Ciproquin. The company was founded on April 26, 1958, and is headquartered in Mumbai, India.

Ambika Cotton Mills

Reasons for buying:

Buy PE was reasonable at 5.08.

The 5-year earnings average is 26% and earnings increasing since 2013 with a slight blip in 2020.

Return on equity is good at 27% but the 5-year average is 16%.

The market cap of the company is ₹931Cr.

The debt of the company is zero with ₹279 Cr cash.

Buy date: 27-Sep-2022

Qty: 6 Buy Price: ₹1,625.45 Buy EPS: ₹319.51 Buy PE: 5.08

I will stop adding when EPS drops below ₹81.27 or R1 does not satisfy.

Ambika Cotton Mills engages in the manufacture of cotton yarns for hosiery and weaving. The Textiles produces compact cotton; hard and soft twist; cylindrical dye cone; and s and z twist yarns. Geographically, the company's business is spread across the world including Asia which accounts for the majority of its revenues.

Mastek

Reasons for buying:

Buy PE was reasonable at 17.17.

The 5-year earnings average is 46% and earnings increasing since 2016.

Return on equity is good at 30% but the 5-year average is 20%.

The market cap of the company is ₹5,239Cr.

The debt of the company is ₹190.26Cr with ₹781.9 Cr cash. I have bought this stock previously.

Buy date: 20-Jun-2022

Qty: 5 Buy Price: ₹1,951 Buy EPS: ₹103.81 Buy PE: 18.79

Buy date: 27-Jul-2022

Qty: 5 Buy Price: ₹1,740.65 Buy EPS: ₹101.29 Buy PE: 17.17

I will stop adding when EPS drops below ₹87.03 or R1 does not satisfy.

Mastek, along with its subsidiaries is a provider of vertically-focused enterprise technology solutions. The company's offering portfolio consists of information technology consulting, application development, application management outsourcing, testing data warehousing, business intelligence, and application security. It also focuses on agile consulting, legacy modernization, oracle cloud, Oracle ERP cloud, product-as-a-service solutions and machine learning, and digital e-commerce. Geographically the company exports its services to the United Kingdom, North America, the middle east, and other regions. The united kingdom region generates maximum revenue for the company.

Zensar Technologies

Reasons for buying:

Buy PE was reasonable at 12.98.

The 5-year earnings average is 12% and earnings increasing since 2012 except in 2017, and 2020.

Return on equity is good at 16.56% but the 5-year average is 15%.

The market cap of the company is ₹5,045 Cr.

Zero debt company with ₹1,019.50 Cr cash. I have bought this stock on three different occasions.

Buy date: 13-Jun-2022

Qty: 35 Buy Price: ₹277.95 Buy EPS: ₹18.27 Buy PE: 15.21

Buy date: 27-Jul-2022

Qty: 40 Buy Price: ₹249.65 Buy EPS: ₹18.27 Buy PE: 13.66

Buy date: 22-Sep-2022

Qty: 45 Buy Price: ₹221.8 Buy EPS: ₹17.08 Buy PE: 12.98

Will stop buying when EPS drops below ₹13.89 or R3 does not satisfy.

Zensar Technologies Ltd provides a range of information technology services and sells IT-related products. The company segments include Digital and Application Services (DAS) and Digital Foundation Services (DFS). It generates maximum revenue from the DAS  segment. The Digital and Application services (DAS) segment is engaged in CUstom Applications Management services that include Application Development, Maintenance, Support Modernization, and Testing services across a wide technology spectrum and Industry verticals. The majority of revenue comes from the United States.

Housing and Urban Development Corporation Ltd

I bought 271 shares on 19-09-2022 at ₹36.9 when the book value is 72. I noticed that from 2018 the book has risen from ₹45.79 to ₹68.39 in 2022 which is 49% raise and on top of that it provided a ₹3.5 dividends this year.

Stop loss or take profit will be at book value will monitor the value every quarter, this investment is part of my book value strategy.